Latest Conference Articles

CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer

CNS-PFS Prolonged With Tucatinib Plus Palbociclib/Letrozole in HR+/HER2+ Breast Cancer

December 8th 2021, 10:52pm

San Antonio Breast Cancer Symposium

A non-chemotherapy–based targeted regimen comprised of tucatinib, palbociclib, and letrozole was found to prolong central nervous system (CNS) progression-free survival (PFS) in patients with hormone receptor–positive, HER2-positive breast cancer.

Premenopausal ER+ Breast Cancer Recurrence Reduced Significantly With Aromatase Inhibitors

Premenopausal ER+ Breast Cancer Recurrence Reduced Significantly With Aromatase Inhibitors

December 8th 2021, 10:14pm

San Antonio Breast Cancer Symposium

Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.

Treatment Options for Patients With HER2+ Breast Cancer With Brain Metastases

Treatment Options for Patients With HER2+ Breast Cancer With Brain Metastases

December 8th 2021, 9:45pm

San Antonio Breast Cancer Symposium

Alexandra S. Zimmer, MD, discusses treatment options for patients with HER2-positive breast cancer who have developed brain metastasis.

Poor Accuracy Seen with Standard IHC in Identifying Low HER2 Expression in Breast Cancer

Poor Accuracy Seen with Standard IHC in Identifying Low HER2 Expression in Breast Cancer

December 8th 2021, 6:44pm

Data presented at the San Antonio Breast Cancer Sympsium found that in patients with a low HER2 immunohistochemistry (IHC) score of 0 or 1+, poor agreement in the evaluation of these patients exist using standard HER2 assays.

Higher Oncotype DX Scores Tied to Persistent Use of Endocrine Treatment in Breast Cancer

Higher Oncotype DX Scores Tied to Persistent Use of Endocrine Treatment in Breast Cancer

December 8th 2021, 5:34pm

San Antonio Breast Cancer Symposium

Patients with higher Oncotype DX scores are more likely to complete the recommended 5 years of endocrine therapy.

Datopotamab Deruxtecan Demonstrates Highly Promising Efficacy in Advanced or Metastatic TNBC

Datopotamab Deruxtecan Demonstrates Highly Promising Efficacy in Advanced or Metastatic TNBC

December 7th 2021, 10:32pm

San Antonio Breast Cancer Symposium

Early results from a phase 1 study show promise for datopotamab deruxtecan for patients with advanced or metastatic triple-negative breast cancer.

Adjuvant Pembrolizumab Continues to Prolong EFS Benefit in TNBC

Adjuvant Pembrolizumab Continues to Prolong EFS Benefit in TNBC

December 7th 2021, 10:18pm

San Antonio Breast Cancer Symposium

Results from prespecified subgroup analyses of the phase KEYNOTE-522 study were presented during 2021 SABCS.

Palbociclib Added to ET Not Beneficial in Early HR+, HER2- Breast Cancer

Palbociclib Added to ET Not Beneficial in Early HR+, HER2- Breast Cancer

December 7th 2021, 9:53pm

Final results from the phase 3 PALLAS study show the addition of palbociclib to endocrine therapy lacks benefit for patients with early hormone receptor-positive, HER2-negative breast cancer.

Pembrolizumab/Chemotherapy Achieves Statistically Significant and Clinically Meaningful Survival Benefit in Metastatic TNBC Subset

Pembrolizumab/Chemotherapy Achieves Statistically Significant and Clinically Meaningful Survival Benefit in Metastatic TNBC Subset

December 7th 2021, 9:41pm

San Antonio Breast Cancer Symposium

Updated results from the phase 3 3KEYNOTE-355 trial indicate a new standard of care for patients with metastatic triple-negative breast cancer in patients with a PD-L1 combined positive score of 10 or higher.

Outcomes in Early Hormone Receptor-Positive or- Negative Breast Cancer Not Improved with Metformin

Outcomes in Early Hormone Receptor-Positive or- Negative Breast Cancer Not Improved with Metformin

December 7th 2021, 7:10pm

San Antonio Breast Cancer Symposium

Improved invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status, was not improved with metformin, according to results of a phase 3 trial.